Therapeutic Advances in Leukemia: Unraveling Molecular and Immune Mechanisms
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: 31 January 2027 | Viewed by 187
Editors
Interests: flow cytometry; cancer immunology; tumor microenvironment; immune checkpoints; leukemia
Interests: cancer immunology; flow cytometry; T follicular helper cells; leukemia
Interests: cancer immunology; macrophages; myeloid-derived suppressor cells; T cells; flow cytometry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Leukemias are a diverse group of blood and bone marrow cancers characterized by the uncontrolled proliferation of aberrant hematopoietic cells. Advances in molecular biology have significantly deepened our understanding of the mechanisms driving leukemia onset and progression. A myriad of molecular alterations, including genetic mutations that disrupt regulatory gene function, perturbations in signaling pathways governing cell proliferation, differentiation, and survival, as well as mechanisms that allow malignant cells to evade programmed cell death (apoptosis), play critical roles in leukemia pathogenesis.
Comprehending the molecular basis of leukemia not only facilitates more precise disease classification and prognostic assessment but also opens new avenues for developing cutting-edge therapeutic strategies. Over recent years, targeted therapies focusing on specific genetic alterations and signaling pathways, immunotherapies that harness the body’s immune system, and epigenetic modulation approaches have emerged as promising treatments. These innovative modalities provide valuable options, especially for patients with leukemia resistant to conventional therapies.
This Special Issue is dedicated to presenting the latest research and achievements in understanding the molecular mechanisms and expanding therapeutic possibilities in leukemia treatment. The collection aims to synthesize current knowledge of the complex molecular processes underlying leukemia development and progression, while highlighting novel therapeutic strategies inspired by recent advances in molecular biology.
We warmly invite submissions of original research articles and comprehensive reviews covering all aspects of leukemia biology and therapy—from fundamental molecular insights to translational studies.
Dr. Agata Szymańska
Dr. Justyna Woś
Dr. Agnieszka Bojarska-Junak
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular diagnostics
- targeted therapy
- immunotherapy
- genetic mutations
- leukemia pathogenesis
- leukemia treatment
- epigenetic regulation
- cancer biomarkers
- hematologic malignancies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
